New medical strategies for midgut carcinoids

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 250-269

  Nilsson, Ola ^a   Arvidsson, Yvonne ^a   Johanson, Viktor ^a   Forssell Aronsson, Eva ^a   Ahlman, Håkan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Angiogenesis inhibition; Growth factor receptor; Monoclonal antibody; Multikinase inhibition; Neuroendocrine tumour; Radionuclide therapy; Small molecule inhibitor; Somatostatin receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE LU 177; 2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; MOTESANIB; OCTREOTIDE; OXALIPLATIN; PAZOPANIB; PEGINTERFERON ALPHA; PLACEBO; RADIOPHARMACEUTICAL AGENT; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VATALANIB;

ANTIANGIOGENIC ACTIVITY; CARCINOID; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; EXPERIMENTAL STUDY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; MIDGUT; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NONHUMAN; REVIEW; TREATMENT OUTCOME;

EID: 77950806023     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009030250     Document Type: Review

References (184)

1. Ahlman, H.; Olausson, M., Surgery of liver metastases in neuroendocrine tumours. In Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach. Blackwell: USA, 2008; pp 632-638.
2. Olausson, M.; Friman, S.; Herlenius, G.; Cahlin, C.; Nilsson, O.; Jansson, S.; Wängberg, B.; Ahlman, H. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl., 2007, 13(3), 327-333. (Pubitemid 46444460)
3. Patel, Y. C.; Greenwood, M. T.; Panetta, R.; Demchyshyn, L.; Niznik, H.; Srikant, C. B. The somatostatin receptor family. Life Sci., 1995, 57(13), 1249-1265.
4. Sharma, K.; Patel, Y. C.; Srikant, C. B. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol. Endocrinol., 1999, 13(1), 82-90. (Pubitemid 29022281)
5. Pages, P.; Benali, N.; Saint-Laurent, N.; Esteve, J. P.; Schally, A. V.; Tkaczuk, J.; Vaysse, N.; Susini, C.; Buscail, L. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J. Biol. Chem., 1999, 274(21), 15186-15193. (Pubitemid 129518858)
6. Kölby, L.; Wängberg, B.; Ahlman, H.; Tisell, L. E.; Fjälling, M.; Forssell-Aronsson, E.; Nilsson, O. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J. Surg., 1998, 22(7), 679-683. (Pubitemid 28277861)
7. Weckbecker, G.; Lewis, I.; Albert, R.; Schmid, H. A.; Hoyer, D.; Bruns, C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov., 2003, 2(12), 999-1017. (Pubitemid 37540581)
8. Boerlin, V.; van der Hoek, J.; Beglinger, C.; Poon, K. W.; Hartmann, S.; Dutreix, C.; Kovarik, J. M.; Bruns, C.; Weckbecker, G.; Lewis, I.; Schnieper, P.; Hofland, L. J.; Lamberts, S. W. New insights on SOM230, a universal somatostatin receptor ligand. J. Endocrinol. Invest., 2003, 26(8 Suppl), 14-16.
9. Rocheville, M.; Lange, D. C.; Kumar, U.; Patel, S. C.; Patel, R. C.; Patel, Y. C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 2000, 288(5463), 154-157.
10. Ahlman, H.; Åhlund, L.; Dahlström, A.; Martner, J.; Stenqvist, O.; Tylen, U. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization. Anesth. Analg., 1988, 67(12), 1142-1148. (Pubitemid 19015581)
11. Rinke, A.; Muller, H. H.; Schade-Brittinger, C.; Klose, K. J.; Barth, P.; Wied, M.; Mayer, C.; Aminossadati, B.; Pape, U. F.; Blaker, M.; Harder, J.; Arnold, C.; Gress, T.; Arnold, R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol., 2009, 27(28), 4656-4663.
12. Kwekkeboom, D. J.; de Herder, W. W.; Kam, B. L.; van Eijck, C. H.; van Essen, M.; Kooij, P. P.; Feelders, R. A.; van Aken, M. O.; Krenning, E. P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26(13), 2124-2130.
13. Schally, A. V. New approaches to the therapy of various tumors based on peptide analogues. Horm. Metab. Res., 2008, 40(5), 315-322.
14. Chaudhry, A.; Funa, K.; Oberg, K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta. Oncol., 1993, 32(2), 107-114. (Pubitemid 23188522)
15. La Rosa, S.; Uccella, S.; Finzi, G.; Albarello, L.; Sessa, F.; Capella, C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum. Pathol., 2003, 34(1), 18-27. (Pubitemid 36160017)
16. Pavel, M. E., Novel treatment. In Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach. Blackwell: USA, 2008; pp. 720-725.
17. Papouchado, B.; Erickson, L. A.; Rohlinger, A. L.; Hobday, T. J.; Erlichman, C.; Ames, M. M.; Lloyd, R. V. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod. Pathol., 2005, 18(10), 1329-1335. (Pubitemid 41348651)
18. Hobday, T. J.; Holen, K.; Donehower, R.; Camoriano, J.; Kim, G.; Picus, J.; Philip, P.; Lloyd, R.; Mahoney, M.; Erlichman, C. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J. Clin. Oncol. (Meeting Abstracts), 2006, 24(18 suppl), 4043-.
19. Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Humblet, Y.; Lopez-Pousa, A.; Hitt, R.; Vega Villegas, M. E.; Duck, L.; Rosine, D.; Amellal, N.; Schueler, A.; Harstrick, A. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol., 2006, 24(18), 2866-2872. (Pubitemid 46630587)
20. Huether, A.; Hopfner, M.; Baradari, V.; Schuppan, D.; Scherubl, H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem. Pharmacol., 2005, 70(11), 1568-1578 (Pubitemid 41540350)
21. Duax, W. L.; Huether, R.; Pletnev, V. Z.; Langs, D.; Addlagatta, A.; Connare, S.; Habegger, L.; Gill, J. Rational genomics I: antisense open reading frames and codon bias in short-chain oxido reductase enzymes and the evolution of the genetic code. Proteins, 2005, 61(4), 900-906. (Pubitemid 41753160)
22. Ciardiello, F.; Troiani, T.; Bianco, R.; Orditura, M.; Morgillo, F.; Martinelli, E.; Morelli, M. P.; Cascone, T.; Tortora, G. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann. Oncol., 2006, 17 (Suppl 7), vii109-14.
23. Kulke, M. H.; Lenz, H. J.; Meropol, N. J.; Posey, J.; Ryan, D. P.; Picus, J.; Bergsland, E.; Stuart, K.; Tye, L.; Huang, X.; Li, J. Z.; Baum, C. M.; Fuchs, C. S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol., 2008, 26(20), 3403-3410.
24. Gross, D. J.; Munter, G.; Bitan, M.; Siegal, T.; Gabizon, A.; Weitzen, R.; Merimsky, O.; Ackerstein, A.; Salmon, A.; Sella, A.; Slavin, S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr. Relat. Cancer, 2006, 13(2), 535-540. (Pubitemid 43886675)
25. Yao, J. C.; Zhang, J. X.; Rashid, A.; Yeung, S. C.; Szklaruk, J.; Hess, K.; Xie, K.; Ellis, L.; Abbruzzese, J. L.; Ajani, J. A. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin. Cancer Res., 2007, 13(1), 234-240
26. McAuliffe, J. C.; Lazar, A. J.; Yang, D.; Steinert, D. M.; Qiao, W.; Thall, P. F.; Raymond, A. K.; Benjamin, R. S.; Trent, J. C. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin. Cancer Res., 2007, 13(22 Pt 1), 6727-6734.
27. Nilsson, B.; Nilsson, O.; Ahlman, H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib - and then? Expert Opin. Investig. Drugs, 2009, 18(4), 457-468.
28. Gazdar, A. F. Activating and resistance mutations of EGFR in nonsmall-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 2009, 28(Suppl 1), S24-31.
29. Wang, L.; Ignat, A.; Axiotis, C. A. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl. Immunohistochem. Mol. Morphol., 2002, 10(2), 139-146.
30. Perren, A.; Komminoth, P.; Saremaslani, P.; Matter, C.; Feurer, S.; Lees, J. A.; Heitz, P. U.; Eng, C. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol., 2000, 157(4), 1097-1103.
31. Zitzmann, K.; De Toni, E. N.; Brand, S.; Goke, B.; Meinecke, J.; Spottl, G.; Meyer, H. H.; Auernhammer, C. J. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology, 2007, 85(1), 54-60.
32. Yao, J. C.; Phan, A. T.; Chang, D. Z.; Wolff, R. A.; Hess, K.; Gupta, S.; Jacobs, C.; Mares, J. E.; Landgraf, A. N.; Rashid, A.; Meric-Bernstam, F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol., 2008, 26(26), 4311-4318
33. Yao, J. C.; Lombard-Bohas, C.; Baudin, E.; Kvols, L. K.; Rougier, P.; Ruszniewski, P.; Hoosen, S.; St Peter, J.; Haas, T.; Lebwohl, D.; Van Cutsem, E.; Kulke, M. H.; Hobday, T. J.; O'Dorisio, T. M.; Shah, M. H.; Cadiot, G.; Luppi, G.; Posey, J. A.; Wiedenmann, B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol., 2010, 28(1), 69-76.
34. Terris, B.; Scoazec, J. Y.; Rubbia, L.; Bregeaud, L.; Pepper, M. S.; Ruszniewski, P.; Belghiti, J.; Flejou, J.; Degott, C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology, 1998, 32(2), 133-138. (Pubitemid 28126179)
35. Pavel, M. E.; Hassler, G.; Baum, U.; Hahn, E. G.; Lohmann, T.; Schuppan, D. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin. Endocrinol. (Oxf), 2005, 62(4), 434-443. (Pubitemid 40503370)
36. Zhang, J.; Jia, Z.; Li, Q.; Wang, L.; Rashid, A.; Zhu, Z.; Evans, D. B.; Vauthey, J. N.; Xie, K.; Yao, J. C. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer, 2007, 109(8), 1478-1486
37. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342 (Pubitemid 38702844)
38. Yao, J. C.; Phan, A.; Hoff, P. M.; Chen, H. X.; Charnsangavej, C.; Yeung, S. C.; Hess, K.; Ng, C.; Abbruzzese, J. L.; Ajani, J. A. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol., 2008, 26(8), 1316-1323
39. Cicek, M.; Iwaniec, U. T.; Goblirsch, M. J.; Vrabel, A.; Ruan, M.; Clohisy, D. R.; Turner, R. R.; Oursler, M. J. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res., 2007, 67(21), 10106-10111. (Pubitemid 350070780)
40. Dahut, W. L.; Lakhani, N. J.; Gulley, J. L.; Arlen, P. M.; Kohn, E. C.; Kotz, H.; McNally, D.; Parr, A.; Nguyen, D.; Yang, S. X.; Steinberg, S. M.; Venitz, J.; Sparreboom, A.; Figg, W. D. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther., 2006, 5(1), 22-27. (Pubitemid 43234973)
41. Rosen, L. S.; Kurzrock, R.; Mulay, M.; Van Vugt, A.; Purdom, M.; Ng, C.; Silverman, J.; Koutsoukos, A.; Sun, Y. N.; Bass, M. B.; Xu, R. Y.; Polverino, A.; Wiezorek, J. S.; Chang, D. D.; Benjamin, R.; Herbst, R. S. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol., 2007, 25(17), 2369-2376. (Pubitemid 46999207)
42. Kumar, R.; Knick, V. B.; Rudolph, S. K.; Johnson, J. H.; Crosby, R. M.; Crouthamel, M. C.; Hopper, T. M.; Miller, C. G.; Harrington, L. E.; Onori, J. A.; Mullin, R. J.; Gilmer, T. M.; Truesdale, A. T.; Epperly, A. H.; Boloor, A.; Stafford, J. A.; Luttrell, D. K.; Cheung, M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther., 2007, 6(7), 2012-2021. (Pubitemid 47052491)
43. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; De Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J. M.; Dewerchin, M.; Collen, D.; Carmeliet, P. Anti-PlGF inhibits growth of VEGF(R)-inhibitorresistant tumors without affecting healthy vessels. Cell, 2007, 131(3), 463-475. (Pubitemid 350007692)
44. Kulke, M. H.; Stuart, K.; Enzinger, P. C.; Ryan, D. P.; Clark, J. W.; Muzikansky, A.; Vincitore, M.; Michelini, A.; Fuchs, C. S. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol., 2006, 24(3), 401-406. (Pubitemid 46630459)
45. Kulke, M. H.; Bergsland, E. K.; Ryan, D. P.; Enzinger, P. C.; Lynch, T. J.; Zhu, A. X.; Meyerhardt, J. A.; Heymach, J. V.; Fogler, W. E.; Sidor, C.; Michelini, A.; Kinsella, K.; Venook, A. P.; Fuchs, C. S. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin. Oncol., 2006, 24(22), 3555-3561. (Pubitemid 46630526)
46. Modlin, I. M.; Moss, S. F.; Chung, D. C.; Jensen, R. T.; Snyderwine, E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J. Natl. Cancer Inst., 2008, 100(18), 1282-1289.
47. Evers, B. M.; Townsend, C. M., Jr.; Upp, J. R.; Allen, E.; Hurlbut, S. C.; Kim, S. W.; Rajaraman, S.; Singh, P.; Reubi, J. C.; Thompson, J. C. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology, 1991, 101(2), 303-311.
48. Pfragner, R.; Wirnsberger, G.; Niederle, B.; Behmel, A.; Rinner, I.; Mandl, A.; Wavrina, F.; Luo, J. S.; Adamiker, D.; Hoegner, H.; Ingolic, E.; Schauenstein, K. Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation. Int. J. Oncol., 1996, 8, 513-520. (Pubitemid 26082169)
49. Kölby, L.; Bernhardt, P.; Ahlman, H.; Wängberg, B.; Johanson, V.; Wigander, A.; Forssell-Aronsson, E.; Karlsson, S.; Ahren, B.; Stenman, G.; Nilsson, O. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transportermediated radionuclide uptake. Am. J. Pathol., 2001, 158(2), 745-755. (Pubitemid 32158636)
50. Van Buren, G., 2nd; Rashid, A.; Yang, A. D.; Abdalla, E. K.; Gray, M. J.; Liu, W.; Somcio, R.; Fan, F.; Camp, E. R.; Yao, J. C.; Ellis, L. M. The development and characterization of a human midgut carcinoid cell line. Clin. Cancer Res., 2007, 13(16), 4704-4712.
51. Pfragner, R.; Behmel, A.; Hoger, H.; Beham, A.; Ingolic, E.; Stelzer, I.; Svejda, B.; Moser, V. A.; Obenauf, A. C.; Siegl, V.; Haas, O.; Niederle, B. Establishment and characterization of three novel cell lines - P-STS, L-STS, H-STS - derived from a human metastatic midgut carcinoid. Anticancer Res., 2009, 29(6), 1951-1961.
52. Nilsson, O.; Kolby, L.; Bernhardt, P.; Forssell-Aronsson, E.; Johanson, V.; Ahlman, H. GOT1 xenografted to nude mice: a unique model for in vivo studies on SSTR-mediated radiation therapy of carcinoid tumors. Ann. N Y Acad. Sci., 2004, 1014, 275-279. (Pubitemid 38594816)
53. Siddique, Z. L.; Drozdov, I.; Floch, J.; Gustafsson, B. I.; Stunes, K.; Pfragner, R.; Kidd, M.; Modlin, I. M. KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model. Neuroendocrinology, 2009, 89(4), 458-470.
54. Sethi, G.; Sung, B.; Aggarwal, B. B. Nuclear Factor-{kappa}B Activation: From Bench to Bedside. Exp. Biol. Med., 2008, 233(1), 21-31.
55. Namba, H.; Saenko, V.; Yamashita, S. Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. Arq. Bras. Endocrinol. Metabol., 2007, 51(5), 843-851.
56. Suh, J.; Payvandi, F.; Edelstein, L. C.; Amenta, P. S.; Zong, W. X.; Gelinas, C.; Rabson, A. B. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate, 2002, 52(3), 183-200. (Pubitemid 34791221)
57. Kojima, M.; Morisaki, T.; Sasaki, N.; Nakano, K.; Mibu, R.; Tanaka, M.; Katano, M. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res., 2004, 24(2B), 675-681. (Pubitemid 38625006)
58. Wang, W.; Abbruzzese, J. L.; Evans, D. B.; Larry, L.; Cleary, K. R.; Chiao, P. J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res., 1999, 5(1), 119-127. (Pubitemid 29045184)
59. Levidou, G.; Saetta, A. A.; Korkolopoulou, P.; Papanastasiou, P.; Gioti, K.; Pavlopoulos, P.; Diamantopoulou, K.; Thomas-Tsagli, E.; Xiromeritis, K.; Patsouris, E. Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch., 2008, 452(3), 295-304.
60. Sweeney, C.; Li, L.; Shanmugam, R.; Bhat-Nakshatri, P.; Jayaprakasan, V.; Baldridge, L. A.; Gardner, T.; Smith, M.; Nakshatri, H.; Cheng, L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res., 2004, 10(16), 5501-5507 (Pubitemid 39100488)
61. Krappmann, D.; Emmerich, F.; Kordes, U.; Scharschmidt, E.; Dorken, B.; Scheidereit, C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene, 1999, 18(4), 943-953. (Pubitemid 29086271)
62. Karin, M.; Yamamoto, Y.; Wang, Q. M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov., 2004, 3(1), 17-26.
63. Olsen, L. S.; Hjarnaa, P. J.; Latini, S.; Holm, P. K.; Larsson, R.; Bramm, E.; Binderup, L.; Madsen, M. W. Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int. J. Cancer, 2004, 111(2), 198-205.
64. Ludwig, L.; Kessler, H.; Wagner, M.; Hoang-Vu, C.; Dralle, H.; Adler, G.; Bohm, B. O.; Schmid, R. M. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RETinduced transformation. Cancer Res., 2001, 61(11), 4526-4535.
65. Svensson, A.; Backman, U.; Jonsson, E.; Larsson, R.; Christofferson, R. CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr. Res., 2002, 51(5), 607-611 (Pubitemid 34453578)
66. Johanson, V.; Arvidsson, Y.; Kölby, L.; Bernhardt, P.; Swärd, C.; Nilsson, O.; Ahlman, H. Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice. Neuroendocrinology, 2005, 82(3-4), 171-176.
67. Olesen, U. H.; Christensen, M. K.; Bjorkling, F.; Jaattela, M.; Jensen, P. B.; Sehested, M.; Nielsen, S. J. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem. Biophys. Res. Commun., 2008, 367(4), 799-804.
68. Hassa, P. O.; Haenni, S. S.; Elser, M.; Hottiger, M. O. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol. Mol. Biol. Rev., 2006, 70(3), 789-829.
69. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADPribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 2006, 7(7), 517-528.
70. Khan, J. A.; Forouhar, F.; Tao, X.; Tong, L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin. Ther. Targets, 2007, 11(5), 695-705. (Pubitemid 46730083)
71. Berger, N. A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res., 1985, 101(1), 4-15. (Pubitemid 15168488)
72. Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res., 2003, 63(21), 7436-7442. (Pubitemid 37413486)
73. Watson, M.; Roulston, A.; Belec, L.; Billot, X.; Marcellus, R.; Bedard, D.; Bernier, C.; Branchaud, S.; Chan, H.; Dairi, K.; Gilbert, K.; Goulet, D.; Gratton, M. O.; Isakau, H.; Jang, A.; Khadir, A.; Koch, E.; Lavoie, M.; Lawless, M.; Nguyen, M.; Paquette, D.; Turcotte, E.; Berger, A.; Mitchell, M.; Shore, G. C.; Beauparlant, P. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell Biol., 2009, 29(21), 5872-5888.
74. von Heideman, A.; Berglund, A.; Larsson, R.; Nygren, P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol., 2009, 65(6), 1165-1172.
75. Roccaro, A. M.; Hideshima, T.; Richardson, P. G.; Russo, D.; Ribatti, D.; Vacca, A.; Dammacco, F.; Anderson, K. C. Bortezomib as an antitumor agent. Curr. Pharm. Biotechnol., 2006, 7(6), 441-448.
76. Larsson, D. E.; Lovborg, H.; Rickardson, L.; Larsson, R.; Öberg, K.; Granberg, D. Identification and evaluation of potential anticancer drugs on human neuroendocrine tumor cell lines. Anticancer Res., 2006, 26(6B), 4125-4129. (Pubitemid 46031481)
77. Shah, M. H.; Young, D.; Kindler, H. L.; Webb, I.; Kleiber, B.; Wright, J.; Grever, M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res., 2004, 10(18 Pt 1), 6111-6118. (Pubitemid 39287516)
78. Baradari, V.; Hopfner, M.; Huether, A.; Schuppan, D.; Scherubl, H. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J. Gastroenterol., 2007, 13(33), 4458-4466. (Pubitemid 47412408)
79. Harris, A. L. Chemotherapy for the carcinoid syndrome. Cancer Chemother. Pharmacol., 1981, 5(3), 133-138.
80. Moertel, C. G. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J. Clin. Oncol., 1983, 1(11), 727-740. (Pubitemid 14202073)
81. Chakravarthy, A.; Abrams, R. A. Radiation therapy in the management of patients with malignant carcinoid tumors. Cancer, 1995, 75(6), 1386-1390.
82. Kulke, M. H.; Mayer, R. J. Carcinoid tumors. N. Engl. J. Med., 1999, 340(11), 858-868.
83. Kimmig, B. N. Radiotherapy for gastroenteropancreatic neuroendocrine tumors. Ann. N Y Acad. Sci., 1994, 733, 488-495.
84. Horton, K. M.; Kamel, I.; Hofmann, L.; Fishman, E. K. Carcinoid tumors of the small bowel: a multitechnique imaging approach. Am. J. Roentgenol., 2004, 182(3), 559-567
85. Samlowski, W. E.; Eyre, H. J.; Sause, W. T. Evaluation of the response of unresectable carcinoid tumors to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12(3), 301-305.
86. Abrams, R. A.; King, D.; Wilson, J. F. Objective response of malignant carcinoid to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 1987, 13(6), 869-873.
87. Keane, T. J.; Rider, W. D.; Harwood, A. R.; Thomas, G. M.; Cummings, B. J. Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumor. Int. J. Radiat. Oncol. Biol. Phys., 1981, 7(11), 1519-1521.
88. Schupak, K. D.; Wallner, K. E. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int. J. Radiat. Oncol. Biol. Phys., 1991, 20(3), 489-495.
89. van Essen, M.; Krenning, E. P.; Kam, B. L.; de Jong, M.; Valkema, R.; Kwekkeboom, D. J. Peptide-receptor radionuclide therapy for endocrine tumors. Nat. Rev. Endocrinol., 2009, 5(7), 382-393.
90. Kölby, L.; Bernhardt, P.; Johanson, V.; Schmitt, A.; Ahlman, H.; Forssell-Aronsson, E.; Mäcke, H.; Nilsson, O. Successful receptormediated radiation therapy of xenografted human midgut carcinoid tumour. Br. J. Cancer, 2005, 93(10), 1144-1151. (Pubitemid 41670699)
91. Oddstig, J.; Bernhardt, P.; Nilsson, O.; Ahlman, H.; Forssell- Aronsson, E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl. Med. Biol., 2006, 33(7), 841-846.
92. Bernhardt, P.; Oddstig, J.; Kölby, L.; Nilsson, O.; Ahlman, H.; Forssell-Aronsson, E. Effects of treatment with (177)Lu-DOTATyr(3)-octreotate on uptake of subsequent injection in carcinoidbearing nude mice. Cancer Biother. Radiopharm., 2007, 22(5), 644-653. (Pubitemid 350059001)
93. Verheij, M.; Bartelink, H. Radiation-induced apoptosis. Cell Tissue Res., 2000, 301(1), 133-142.
94. Shinomiya, N. New concepts in radiation-induced apoptosis: "premitotic apoptosis" and "postmitotic apoptosis". J. Cell Mol. Med., 2001, 5(3), 240-253.
95. Hamada, N.; Matsumoto, H.; Hara, T.; Kobayashi, Y. Intercellular and intracellular signaling pathways mediating ionizing radiationinduced bystander effects. J. Radiat. Res. (Tokyo), 2007, 48(2), 87-95. (Pubitemid 46535892)
96. Zhou, H.; Ivanov, V. N.; Gillespie, J.; Geard, C. R.; Amundson, S. A.; Brenner, D. J.; Yu, Z.; Lieberman, H. B.; Hei, T. K. Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway. Proc. Natl. Acad. Sci. USA, 2005, 102(41), 14641-14646.
97. Azzam, E. I.; De Toledo, S. M.; Spitz, D. R.; Little, J. B. Oxidative metabolism modulates signal transduction and micronucleus formation in bystander cells from alpha-particle-irradiated normal human fibroblast cultures. Cancer Res., 2002, 62(19), 5436-5442.
98. Zhou, H.; Suzuki, M.; Randers-Pehrson, G.; Vannais, D.; Chen, G.; Trosko, J. E.; Waldren, C. A.; Hei, T. K. Radiation risk to low fluences of alpha particles may be greater than we thought. Proc. Natl. Acad. Sci. USA, 2001, 98(25), 14410-14415.
99. Cadden, I.; Johnston, B. T.; Turner, G.; McCance, D.; Ardill, J.; McGinty, A. An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours. Neuroendocrinology, 2007, 86(2), 104-111. (Pubitemid 47494210)
100. Schulze-Bergkamen, H.; Weinmann, A.; Moehler, M.; Siebler, J.; Galle, P. R. Novel ways to sensitise gastrointestinal cancer to apoptosis. Gut, 2009, 58(7), 1010-1024.
101. Wang, D. G. Apoptosis in neuroendocrine tumours. Clin. Endocrinol. (Oxf), 1999, 51(1), 1-9.
102. Wang, D. G.; Johnston, C. F.; Anderson, N.; Sloan, J. M.; Buchanan, K. D. Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J. Pathol., 1995, 175(4), 397-401.
103. Pasquini, L.; Petrucci, E.; Riccioni, R.; Petronelli, A.; Testa, U. Sensitivity and resistance of human cancer cells to TRAIL: mechanisms and therapeutical perspectives. Cancer Ther., 2006, 4, 47-72.
104. Griffith, T. S.; Stokes, B.; Kucaba, T. A.; Earel, J. K., Jr.; VanOosten, R. L.; Brincks, E. L.; Norian, L. A. TRAIL gene therapy: from preclinical development to clinical application. Curr. Gene Ther., 2009, 9(1), 9-19.
105. Johnstone, R. W.; Frew, A. J.; Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer, 2008, 8(10), 782-798.
106. Ashkenazi, A.; Dixit, V. M. Death receptors: signaling and modulation. Science, 1998, 281(5381), 1305-1308.
107. Kim, Y.; Suh, N.; Sporn, M.; Reed, J. C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-nduced apoptosis. J. Biol. Chem., 2002, 277(25), 22320-22329.
108. Schuchmann, M.; Schulze-Bergkamen, H.; Fleischer, B.; Schattenberg, J. M.; Siebler, J.; Weinmann, A.; Teufel, A.; Worns, M.; Fischer, T.; Strand, S.; Lohse, A. W.; Galle, P. R. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol. Rep., 2006, 15(1), 227-230
109. Koschny, R.; Walczak, H.; Ganten, T. M. The promise of TRAIL otential and risks of a novel anticancer therapy. J. Mol. Med., 2007, 85(9), 923-935.
110. Goke, R.; Goke, A.; Goke, B.; El-Deiry, W. S.; Chen, Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion, 2001, 64(2), 75-80. (Pubitemid 34701873)
111. Kuwabara, M.; Takahashi, K.; Inanami, O. Induction of apoptosis through the activation of SAPK/JNK followed by the expression of death receptor Fas in X-irradiated cells. J. Radiat. Res. (Tokyo), 2003, 44(3), 203-209. (Pubitemid 38738723)
112. Inanami, O.; Takahashi, K.; Kuwabara, M. Attenuation of caspase-3-dependent apoptosis by Trolox post-treatment of X-irradiated MOLT-4 cells. Int. J. Radiat. Biol., 1999, 75(2), 155-163. (Pubitemid 29089154)
113. McKenna, W. G.; Muschel, R. J.; Gupta, A. K.; Hahn, S. M.; Bernhard, E. J. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene, 2003, 22(37), 5866-5875. (Pubitemid 37176707)
114. Ling, C. C.; Endlich, B. Radioresistance induced by oncogenic transformation. Radiat Res., 1989, 120(2), 267-279
115. Bernhard, E. J.; Kao, G.; Cox, A. D.; Sebti, S. M.; Hamilton, A. D.; Muschel, R. J.; McKenna, W. G. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res., 1996, 56(8), 1727-1730 (Pubitemid 26119651)
116. Miller, A. C.; Kariko, K.; Myers, C. E.; Clark, E. P.; Samid, D. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer, 1993, 53(2), 302-307 (Pubitemid 23042883)
117. Lettini, A. A.; Guidoboni, M.; Fonsatti, E.; Anzalone, L.; Cortini, E.; Maio, M. Epigenetic remodelling of DNA in cancer. Histol. Histopathol., 2007, 22(12), 1413-1424.
118. Liu, L.; Broaddus, R. R.; Yao, J. C.; Xie, S.; White, J. A.; Wu, T. T.; Hamilton, S. R.; Rashid, A. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod. Pathol., 2005, 18(12), 1632-1640. (Pubitemid 41670664)
119. Arnold, C. N.; Sosnowski, A.; Schmitt-Graff, A.; Arnold, R.; Blum, H. E. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int. J. Cancer, 2007, 120(10), 2157-2164.
120. Zhang, H. Y.; Rumilla, K. M.; Jin, L.; Nakamura, N.; Stilling, G. A.; Ruebel, K. H.; Hobday, T. J.; Erlichman, C.; Erickson, L. A.; Lloyd, R. V. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. Endocrine, 2006, 30(3), 299-306.
121. Choi, I. S.; Estecio, M. R.; Nagano, Y.; Kim do, H.; White, J. A.; Yao, J. C.; Issa, J. P.; Rashid, A. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod. Pathol., 2007, 20(7), 802-810.
122. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5(9), 769-784. (Pubitemid 44348499)
123. Qi, R.; An, H.; Yu, Y.; Zhang, M.; Liu, S.; Xu, H.; Guo, Z.; Cheng, T.; Cao, X. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res., 2003, 63(23), 8323-8329. (Pubitemid 37549485)
124. Sriuranpong, V.; Borges, M. W.; Ravi, R. K.; Arnold, D. R.; Nelkin, B. D.; Baylin, S. B.; Ball, D. W. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res., 2001, 61(7), 3200-3205.
125. Sippel, R. S.; Carpenter, J. E.; Kunnimalaiyaan, M.; Chen, H. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery, 2003, 134(6), 866-871; discussion 871-873
126. Nakakura, E. K.; Sriuranpong, V. R.; Kunnimalaiyaan, M.; Hsiao, E. C.; Schuebel, K. E.; Borges, M. W.; Jin, N.; Collins, B. J.; Nelkin, B. D.; Chen, H.; Ball, D. W. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J. Clin. Endocrinol. Metab., 2005, 90(7), 4350-4356.
127. Roncarati, R.; Sestan, N.; Scheinfeld, M. H.; Berechid, B. E.; Lopez, P. A.; Meucci, O.; McGlade, J. C.; Rakic, P.; D'Adamio, L. The gamma-secretase- generated intracellular domain of betaamyloid precursor protein binds Numb and inhibits Notch signaling. Proc. Natl. Acad. Sci. USA, 2002, 99(10), 7102-7107. (Pubitemid 34526262)
128. Fischer, D. F.; van Dijk, R.; Sluijs, J. A.; Nair, S. M.; Racchi, M.; Levelt, C. N.; van Leeuwen, F. W.; Hol, E. M. Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP. FASEB J., 2005, 19(11), 1451-1458.
129. Arvidsson, Y.; Andersson, E.; Bergström, A.; Andersson, M. K.; Altiparmak, G.; Illerskog, A. C.; Ahlman, H.; Lamazhapova, D.; Nilsson, O.
130. Stockhausen, M. T.; Sjölund, J.; Manetopoulos, C.; Axelson, H. Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br. J. Cancer, 2005, 92(4), 751-759. (Pubitemid 40460614)
131. Greenblatt, D. Y.; Vaccaro, A. M.; Jaskula-Sztul, R.; Ning, L.; Haymart, M.; Kunnimalaiyaan, M.; Chen, H. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist, 2007, 12(8), 942-951.
132. Kummar, S.; Gutierrez, M.; Gardner, E. R.; Donovan, E.; Hwang, K.; Chung, E. J.; Lee, M. J.; Maynard, K.; Kalnitskiy, M.; Chen, A.; Melillo, G.; Ryan, Q. C.; Conley, B.; Figg, W. D.; Trepel, J. B.; Zwiebel, J.; Doroshow, J. H.; Murgo, A. J. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res., 2007, 13(18 Pt 1), 5411-5417.
133. Shah, M. H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra, Y.; Young, D.; Grever, M. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res., 2006, 12(13), 3997-4003. (Pubitemid 44078086)
134. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410(6824), 50-56. (Pubitemid 32225831)
135. Taichman, R. S.; Cooper, C.; Keller, E. T.; Pienta, K. J.; Taichman, N. S.; McCauley, L. K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res., 2002, 62(6), 1832-1837.
136. Kang, Y.; Siegel, P. M.; Shu, W.; Drobnjak, M.; Kakonen, S. M.; Cordon-Cardo, C.; Guise, T. A.; Massague, J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3(6), 537-549. (Pubitemid 36808649)
137. Balkwill, F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol., 2004, 14(3), 171-179. (Pubitemid 38586742)
138. Sun, Y. X.; Schneider, A.; Jung, Y.; Wang, J.; Dai, J.; Wang, J.; Cook, K.; Osman, N. I.; Koh-Paige, A. J.; Shim, H.; Pienta, K. J.; Keller, E. T.; McCauley, L. K.; Taichman, R. S. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res., 2005, 20(2), 318-329.
139. Arvidsson, Y.; Bergström, A.; Arvidsson, L.; Kristiansson, E.; Ahlman, H.; Nilsson, O. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr. Relat. Cancer, 2010, 17(2), 303-316.
140. Nevo, I.; Sagi-Assif, O.; Meshel, T.; Geminder, H.; Goldberg-Bittman, L.; Ben-Menachem, S.; Shalmon, B.; Goldberg, I.; Ben- Baruch, A.; Witz, I. P. The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. Immunol. Lett., 2004, 92(1-2), 163-169.
141. Burger, M.; Glodek, A.; Hartmann, T.; Schmitt-Graff, A.; Silberstein, L. E.; Fujii, N.; Kipps, T. J.; Burger, J. A. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 2003, 22(50), 8093-8101.
142. Laird, D. J.; von Andrian, U. H.; Wagers, A. J. Stem cell trafficking in tissue development, growth, and disease. Cell, 2008, 132(4), 612-630.
143. Murakami, T.; Maki, W.; Cardones, A. R.; Fang, H.; Tun Kyi, A.; Nestle, F. O.; Hwang, S. T. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res., 2002, 62(24), 7328-7334.
144. Smith, M. C.; Luker, K. E.; Garbow, J. R.; Prior, J. L.; Jackson, E.; Piwnica-Worms, D.; Luker, G. D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res., 2004, 64(23), 8604-8612. (Pubitemid 39552073)
145. Yoon, Y.; Liang, Z.; Zhang, X.; Choe, M.; Zhu, A.; Cho, H. T.; Shin, D. M.; Goodman, M. M.; Chen, Z. G.; Shim, H. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res., 2007, 67(15), 7518-7524. (Pubitemid 47206582)
146. Kajiyama, H.; Shibata, K.; Terauchi, M.; Ino, K.; Nawa, A.; Kikkawa, F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int. J. Cancer, 2008, 122(1), 91-99. (Pubitemid 350209982)
147. Kim, S. Y.; Lee, C. H.; Midura, B. V.; Yeung, C.; Mendoza, A.; Hong, S. H.; Ren, L.; Wong, D.; Korz, W.; Merzouk, A.; Salari, H.; Zhang, H.; Hwang, S. T.; Khanna, C.; Helman, L. J. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis, 2008, 25(3), 201-211.
148. Menu, E.; Asosingh, K.; Indraccolo, S.; De Raeve, H.; Van Riet, I.; Van Valckenborgh, E.; Vande Broek, I.; Fujii, N.; Tamamura, H.; Van Camp, B.; Vanderkerken, K. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica, 2006, 91(5), 605-612. (Pubitemid 43799454)
149. Larsson, O.; Girnita, A.; Girnita, L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer, 2005, 92(12), 2097-2101. (Pubitemid 40966242)
150. Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Axelson, M.; Girnita, L.; Larsson, O. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene, 2008, 27(11), 1629-1638. (Pubitemid 351347881)
151. Vitale, L.; Lenzi, L.; Huntsman, S. A.; Canaider, S.; Frabetti, F.; Casadei, R.; Facchin, F.; Carinci, P.; Zannotti, M.; Coppola, D.; Strippoli, P. Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors. Oncol. Rep., 2006, 15(5), 1249-1256.
152. von Wichert, G.; Jehle, P. M.; Hoeflich, A.; Koschnick, S.; Dralle, H.; Wolf, E.; Wiedenmann, B.; Boehm, B. O.; Adler, G.; Seufferlein, T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res., 2000, 60(16), 4573-4581 (Pubitemid 32103642)
153. Van Gompel, J. J.; Chen, H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery, 2004, 136(6), 1297-1302. (Pubitemid 39647548)
154. Höpfner, M.; Baradari, V.; Huether, A.; Schofl, C.; Scherubl, H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer, 2006, 13(1), 135-149.
155. Nilsson, O.; Wängberg, B.; Theodorsson, E.; Skottner, A.; Ahlman, H. Presence of IGF-I in human midgut carcinoid tumours - an autocrine regulator of carcinoid tumour growth? Int. J. Cancer, 1992, 51(2), 195-203.
156. Laurent-Puig, P.; Lievre, A.; Blons, H. Mutations and response to epidermal growth factor receptor inhibitors. Clin. Cancer Res., 2009, 15(4), 1133-1139.
157. Bergmann, F.; Breinig, M.; Hopfner, M.; Rieker, R. J.; Fischer, L.; Kohler, C.; Esposito, I.; Kleeff, J.; Herpel, E.; Ehemann, V.; Friess, H.; Schirmacher, P.; Kern, M. A. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am. J. Gastroenterol., 2009, 104(1), 171-181.
158. Höpfner, M.; Sutter, A. P.; Gerst, B.; Zeitz, M.; Scherubl, H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br. J. Cancer, 2003, 89(9), 1766-1775 (Pubitemid 37464152)
159. Kidd, M.; Eick, G. N.; Modlin, I. M.; Pfragner, R.; Champaneria, M. C.; Murren, J. Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J. Mol. Endocrinol., 2007, 38(1-2), 181-192. (Pubitemid 46351602)
160. Nilsson, O.; Wängberg, B.; Kölby, L.; Schultz, G. S.; Ahlman, H. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int. J. Cancer, 1995, 60(5), 645-651.
161. Tian, M.; Schiemann, W. P. The TGF-beta paradox in human cancer: an update. Future Oncol., 2009, 5(2), 259-271.
162. Moustakas, A.; Heldin, C. H. The regulation of TGFbeta signal transduction. Development, 2009, 136(22), 3699-3714.
163. Ishizuka, J.; Beauchamp, R. D.; Sato, K.; Townsend, C. M., Jr.; Thompson, J. C. Novel action of transforming growth factor beta 1 in functioning human pancreatic carcinoid cells. J. Cell Physiol., 1993, 156(1), 112-118. (Pubitemid 23211269)
164. Wimmel, A.; Wiedenmann, B.; Rosewicz, S. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells. Gut, 2003, 52(9), 1308-1316. (Pubitemid 37026464)
165. Leu, F. P.; Nandi, M.; Niu, C. The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling. Mol. Cancer Res., 2008, 6(6), 1029-1042.
166. Kidd, M.; Modlin, I. M.; Pfragner, R.; Eick, G. N.; Champaneria, M. C.; Chan, A. K.; Camp, R. L.; Mane, S. M. Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. Cancer, 2007, 109(12), 2420-2431.
167. Massague, J. TGFbeta in cancer. Cell, 2008, 134(2), 215-230.
168. Bold, R. J.; Ishizuka, J.; Rajaraman, S.; Perez-Polo, J. R.; Townsend, C. M., Jr.; Thompson, J. C. Nerve growth factor as a mitogen for a pancreatic carcinoid cell line. J. Neurochem., 1995, 64(6), 2622-2628.
169. Kunnimalaiyaan, M.; Ndiaye, M.; Chen, H. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery, 2006, 140(6), 1009-1014; discussion 1014-1015
170. Nicholson, K. M.; Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal, 2002, 14(5), 381-395.
171. Pitt, S. C.; Chen, H.; Kunnimalaiyaan, M. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J. Am. Coll. Surg., 2009, 209(1), 82-88.
172. Liu, H.; Radisky, D. C.; Nelson, C. M.; Zhang, H.; Fata, J. E.; Roth, R. A.; Bissell, M. J. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc. Natl. Acad. Sci. USA, 2006, 103(11), 4134-4139.
173. Wu, C.; Huang, J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J. Biol. Chem., 2007, 282(6), 3571-3583 (Pubitemid 47084471)
174. Toulany, M.; Kehlbach, R.; Florczak, U.; Sak, A.; Wang, S.; Chen, J.; Lobrich, M.; Rodemann, H. P. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcsdependent DNA double-strand break repair. Mol. Cancer Ther., 2008, 7(7), 1772-1781.
175. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892), 949-954. (Pubitemid 34716871)
176. Younes, N.; Fulton, N.; Tanaka, R.; Wayne, J.; Straus, F. H., 2nd; Kaplan, E. L. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer, 1997, 79(9), 1804-1808.
177. Tannapfel, A.; Vomschloss, S.; Karhoff, D.; Markwarth, A.; Hengge, U. R.; Wittekind, C.; Arnold, R.; Horsch, D. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am. J. Clin. Pathol., 2005, 123(2), 256-260. (Pubitemid 40194088)
178. Karhoff, D.; Sauer, S.; Schrader, J.; Arnold, R.; Fendrich, V.; Bartsch, D. K.; Horsch, D. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology, 2007, 85(1), 45-53. (Pubitemid 46550025)
179. Van Gompel, J. J.; Kunnimalaiyaan, M.; Holen, K.; Chen, H. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol. Cancer Ther., 2005, 4(6), 910-917. (Pubitemid 40909073)
180. Hall-Jackson, C. A.; Eyers, P. A.; Cohen, P.; Goedert, M.; Boyle, F. T.; Hewitt, N.; Plant, H.; Hedge, P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol., 1999, 6(8), 559-568. (Pubitemid 29380770)
181. Chen, H.; Udelsman, R.; Zeiger, M. A.; Ball, D. A. Human achaete-scute homolog-1 is higly expressed in a subset of neuroendocrine tumours. Oncol. Rep., 1997, 4, 775-778.
182. Lanigan, T. M.; DeRaad, S. K.; Russo, A. F. Requirement of the MASH-1 transcription factor for neuroendocrine differentiation of thyroid C cells. J. Neurobiol., 1998, 34(2), 126-134. (Pubitemid 28067141)
183. Lo, L. C.; Johnson, J. E.; Wuenschell, C. W.; Saito, T.; Anderson, D. J. Mammalian achaete-scute homolog 1 is transiently expressed by spatially restricted subsets of early neuroepithelial and neural crest cells. Genes Dev., 1991, 5(9), 1524-1537.
184. Jiang, S. X.; Kameya, T.; Asamura, H.; Umezawa, A.; Sato, Y.; Shinada, J.; Kawakubo, Y.; Igarashi, T.; Nagai, K.; Okayasu, I. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod. Pathol., 2004, 17(2), 222-229.